Q-VANT operates two manufacturing facilities in Los Angeles, Chile, specializing in the purification of saponin adjuvants. These facilities are equipped with large-scale production capacity to meet the global pharmaceutical demands of saponin adjuvants and can be readily expanded for increased capacity.
Facilities for Industrial Volume
Affordable and stable cost
Q-SAP technology allows the obtention of pure molecules from varied quillaja biomass, at affordable cost for public vaccination programs, emancipating from the limited availability, the high and volatile cost of quillaja bark.
Los Angeles manufacturing facilities (CL)
- Manufacturing of starting material and veterinary adjuvant.
- Saponin fractionation at scale (in 2026).
- Close to the biomass harvesting.
Santiago R&D facilities (CL)
- Research and development for saponin adjuvants
- Development of manufacturing processes.
- Capabilities for purification, fractionation, characterization, formulation, exploratory studies.
